Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
-
September 10 :Immunic's MS R&D Day. Management ofImmunic , includingDaniel Vitt , Ph.D., Chief Executive Officer;Jason Tardio , M.B.A., Chief Operating Officer and President;Andreas Muehler , M.D., M.B.A., Chief Medical Officer; andHella Kohlhof , Ph.D., Chief Scientific Officer, will be joined by two of the MS industry's renowned experts to discuss the MS landscape as well asImmunic's orally available lead-asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) and its potential to become the treatment of choice for both relapsing and progressive MS patients.- Date:
Tuesday, September 10, 2024 - Time:
10:30 am to 12:30 pm ET , followed by a networking lunch - Location: One Five One,
151 West 42nd Street ,New York, NY 10036 - Featured Experts:
- Francesca Montarolo, Ph.D., Neuroscience Institute
Cavalieri Ottolenghi (NICO) and University Hospital San Luigi Gonzaga of Orbassano,Turin, Italy Amit Bar-Or , M.D., FRCPC, Melissa and Paul Anderson Distinguished Chair, Director,Center for Neuroinflammation and Experimental Therapeutics , Chief, Multiple Sclerosis Division,Department of Neurology ,Perelman School of Medicine ,University of Pennsylvania
- Francesca Montarolo, Ph.D., Neuroscience Institute
- To register, please RSVP by sending an email to: ir@imux.com.
- Date:
-
September 18-20 : 40thCongress of theEuropean Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Members ofImmunic's management, medical, clinical and preclinical teams will attend this conference inCopenhagen, Denmark . Data on vidofludimus calcium will be presented in an oral presentation and three ePosters. Additionally, the team will be available throughout the event at booth #60. All poster presentations will be accessible on the "Events and Presentations" section ofImmunic's website at: https://ir.imux.com/events-and-presentations.
Oral Poster Presentation:
-
- Title: Serum Neurofilament Changes in Progressive MS: Exploring the Impact of Vidofludimus Calcium by Age and Disability in the CALLIPER Study Interim Analysis
-
Presenting Author:
Robert J. Fox , Staff Neurologist,Mellon Center for Multiple Sclerosis , Vice-Chair for Research,Neurological Institute ,Cleveland Clinic ,Cleveland, Ohio - Poster Number: P753
- Session Title: Poster Session 2
-
Session Date:
Thursday, September 19, 2024 -
Session Time:
4:45 pm –6:45 pm CEST
ePosters:
-
- Title: Exploring the Potential of Vidofludimus Calcium to Reduce Fatigue in Multiple Sclerosis by Preventing Epstein-Barr Virus Reactivation
- ePoster Number: P1119
- Title: Vidofludimus Calcium Activity on NURR1 in Preclinical Models: A Potential Neuroprotective Function in Multiple Sclerosis
- ePoster Number: P1410
- Title: Vidofludimus Calcium Shows T Helper Cell Modulatory Effects in Murine Experimental Autoimmune Encephalomyelitis: One of the Potential Mode of Action Pathways for MS Treatment
- ePoster Number: P1390
-
September 2-4 : DMDG 50th Open Meeting 2024.Juliano R. Fonseca , Ph.D., Head of Preclinical Development atImmunic , will present data fromImmunic's phase 1, open-label mass balance and pharmacokinetics study of vidofludimus calcium in a poster presentation at this meeting inYork, United Kingdom .- Title:
Mass Balance and ADME Properties of [14C]-IMU-838 Following Oral Administration to Healthy Male Subjects - The presentation and specific details regarding poster number and session will be accessible on the "Events and Presentations" section of
Immunic's website at: https://ir.imux.com/events-and-presentations, once they are available.
- Title:
-
September 5-7 : 20th International Celiac Disease Symposium ICDS.Martina Wirth , Senior Manager Translational Pharmacology atImmunic , will present data fromImmunic's phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator targeting SIRT6 (Sirtuin 6), in patients with celiac disease, in a late-breaking poster presentation at this symposium inSheffield, United Kingdom .- Title: First-In-Human Trial of IMU-856, an Orally Available Epigenetic Modulator of Barrier Function and Regeneration for the Treatment of Celiac Disease
- The presentation and specific details regarding poster number and session will be accessible on the "Events and Presentations" section of
Immunic's website at: https://ir.imux.com/events-and-presentations, once they are available.
-
September 17-19 : 2024Cantor Fitzgerald Global Healthcare Conference .Dr. Vitt will participate in a fireside chat at this conference inNew York onWednesday, September 18, 2024 , at3:05 pm ET . A webcast of the presentation will be available on the "Events and Presentations" section ofImmunic's website at: https://ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.
About
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in investor and scientific conferences.
Contact Information
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
+1 917 633 7790
immunic@rxir.com
US Media Contact
+1 212 896 1241
ckasunich@ksca.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/immunic-to-host-multiple-sclerosis-rd-day-and-participate-in-scientific-and-investor-conferences-in-september-302232141.html
SOURCE